Heidi Overton’s anticipated nomination reflects prioritization of White House policy alignment, particularly on vaccines and pricing, over traditional FDA operational leadership pedigrees. Senate ...

"The Current Vitiligo Treatment Landscape, From Topicals to Orals" takes up the question of where each modality — topicals, phototherapy, orals, and procedures — fits into the ...

In "How JAK Inhibitors Are Reshaping Vitiligo Treatment Goals," Dr. Desai and Dr. Lal explore how JAK inhibitors are ...

Adaptive trials like I-SPY have lifted breast cancer complete response rates to 50%–60%, but better early end points are needed for wider use.

Quantification across 204 countries attributed CKD DALYs to seven dietary risks and four etiologic categories (T2D, ...

After adjustment for demographic and clinical risk factors, discrimination in each domain was associated with higher heart failure risk, and risk increased with cumulative exposure. Women who reported ...

Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are ...

An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change ...

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA. The FDA has granted an accelerated approval to the regimen ...

Closed-loop referral systems confirm outcomes, not just referrals, avoiding false success and building durable, scalable social care infrastructure. Social care programs that stop at the referral ...

Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...